89 related articles for article (PubMed ID: 18337654)
21. Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Lopez V; Pinazo I; Marti N; Monteagudo C; Jorda E
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):959-60. PubMed ID: 18785888
[No Abstract] [Full Text] [Related]
22. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Dal Lago L; D'Hondt V; Awada A
Oncologist; 2008 Aug; 13(8):845-58. PubMed ID: 18695262
[TBL] [Abstract][Full Text] [Related]
23. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
Ruppin S; Protzel C; Klebingat KJ; Hakenberg OW
Eur Urol; 2009 Apr; 55(4):986-8; quiz 988. PubMed ID: 19004541
[TBL] [Abstract][Full Text] [Related]
24. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Spector E; Franklin MJ; Truskinovsky AM; Dudek AZ
Acta Oncol; 2010; 49(1):104-6. PubMed ID: 19711206
[No Abstract] [Full Text] [Related]
26. Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
Robert C; Mateus C; Spatz A; Wechsler J; Escudier B
J Am Acad Dermatol; 2009 Feb; 60(2):299-305. PubMed ID: 19028406
[TBL] [Abstract][Full Text] [Related]
27. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
Arnault JP; Wechsler J; Escudier B; Spatz A; Tomasic G; Sibaud V; Aractingi S; Grange JD; Poirier-Colame V; Malka D; Soria JC; Mateus C; Robert C
J Clin Oncol; 2009 Aug; 27(23):e59-61. PubMed ID: 19597016
[No Abstract] [Full Text] [Related]
28. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
29. Defining lower limb lymphedema after inguinal or ilio-inguinal dissection in patients with melanoma using classification and regression tree analysis.
Spillane AJ; Saw RP; Tucker M; Byth K; Thompson JF
Ann Surg; 2008 Aug; 248(2):286-93. PubMed ID: 18650640
[TBL] [Abstract][Full Text] [Related]
30. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
31. A distinct cutaneous reaction to sorafenib and a multikinase inhibitor.
Joncas V; Sammour R; Krasny M; Bouffard D; Provost N
Int J Dermatol; 2008 Jul; 47(7):767-9. PubMed ID: 18613894
[No Abstract] [Full Text] [Related]
32. Sorafenib for metastatic renal cancer: the Princess Margaret experience.
Riechelmann RP; Chin S; Wang L; Tannock IF; Berthold DR; Moore MJ; Knox JJ
Am J Clin Oncol; 2008 Apr; 31(2):182-7. PubMed ID: 18391604
[TBL] [Abstract][Full Text] [Related]
33. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
Kelley RK; Venook AP
J Clin Oncol; 2008 Dec; 26(36):5845-8. PubMed ID: 19029408
[No Abstract] [Full Text] [Related]
35. Severe cutaneous reaction to sorafenib: induction of tolerance.
Bauer C; Przybilla B; Ruëff F
Acta Derm Venereol; 2008; 88(6):627-8. PubMed ID: 19002355
[No Abstract] [Full Text] [Related]
36. Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib.
Baumann M; Cerny T; Sommacal A; Koeberle D
Hematol Oncol; 2012 Jun; 30(2):101-4. PubMed ID: 21732400
[TBL] [Abstract][Full Text] [Related]
37. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Bianchi G; Loibl S; Zamagni C; Salvagni S; Raab G; Siena S; Laferriere N; Peña C; Lathia C; Bergamini L; Gianni L
Anticancer Drugs; 2009 Aug; 20(7):616-24. PubMed ID: 19739318
[TBL] [Abstract][Full Text] [Related]
38. Medical therapies to extend survival in hepatocellular carcinoma.
Gish R; Marrero JB; Tong MJ
Clin Adv Hematol Oncol; 2008 Aug; 6(8):1-14; quiz 15. PubMed ID: 18833600
[TBL] [Abstract][Full Text] [Related]
39. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
Amin C; Wallen E; Pruthi RS; Calvo BF; Godley PA; Rathmell WK
Urology; 2008 Oct; 72(4):864-8. PubMed ID: 18684493
[TBL] [Abstract][Full Text] [Related]
40. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
